Close Menu

Synthetic Biology

The method can be used with isothermal amplification and paper-based readouts to detect infectious disease drug resistance in low-resource areas.

The DNA synthesis company priced shares of common stock at $28 and increased the expected proceeds from its stock offering to $130 million.

The offering of common stock will be the second for Twist this year and the third since the company made its initial public offering in October 2018.

On a conference call to discuss the firm's fiscal Q1 financial results, Twist executives detailed the firm's vision for near- and long-term growth.

A hearing scheduled for Friday, part of a lawsuit filed by Agilent was cancelled, leading to speculation the sides were close to a settlement.

Kelvin Droegemeier, the director of the White House Office of Science and Technology Policy, is the new acting director of the US National Science Foundation.

An opinion piece at the Guardian discusses the state of SARS-CoV-2 testing in the UK.

Wired reports the University of California, Berkeley's Innovative Genomics Institute has transformed itself into a diagnostic lab to run SARS-CoV-2 tests.

In Nature this week: direct-capture Perturb-seq approach for combinatorial single-cell CRISPR screens, potential uses of genome-editing in breeding crops, and more.